Enhanced fractional catabolic rate of apo A-I and apo A-II in heterozygous subjects for apo A-IZaragoza (L144R)

Atherosclerosis

Volumn 154, Issue 3, 2001, Pages 613-623

  Recalde, Delia ^a   Velez Carrasco, Wanda ^b   Civeira, Fernando ^c   Cenarro, Ana ^c   Gomez Coronado, Diego ^d   Ordovas, Jose M ^b   Pocovi, Miguel ^a  

^a UNIVERSITY OF ZARAGOZA   (Spain)

^b TUFTS UNIVERSITY   (United States)

^c HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

^d HOSPITAL RAMÓN Y CAJAL   (Spain)

Author keywords

Apo A I; Apo A IZaragoza L144R; Apo A II; Fractional catabolic rate; Hypoalphalipoproteinemia; Stable isotopes

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN A2; CARRIER PROTEIN; CHOLESTEROL ESTER; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; ISOPROTEIN; LEUCINE; MUTANT PROTEIN; PHOSPHATIDYLCHOLINE STEROL ACYLTRANSFERASE; TRIACYLGLYCEROL;

ADOLESCENT; ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL ESTERIFICATION; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; ENZYME ACTIVATION; ENZYME ACTIVITY; FEMALE; HETEROZYGOSITY; HUMAN; LIPID COMPOSITION; LIPOPROTEIN BLOOD LEVEL; LIPOPROTEIN METABOLISM; LIPOPROTEIN SECRETION; MALE; PEDIGREE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN VARIANT;

ADULT; APOLIPOPROTEIN A-I; APOLIPOPROTEIN A-II; CASE-CONTROL STUDIES; CHOLESTEROL, HDL; HETEROZYGOTE; HUMANS; MALE; PEDIGREE; REFERENCE VALUES;

EID: 0035864652     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(00)00555-4     Document Type: Article

References (72)

1. Plasma high-density lipoprotein metabolism and relationship to atherogenesis
2. Familial lipoprotein disorders in patients with premature coronary artery disease
3. Familial hypoalphalipoproteinemia
4. The amphipatic: Helix in the exchangeable apolipoproteins: A review of secondary structure and function
5. Molecular physiology of reverse cholesterol transport
6. Apolipoprotein multigene family: Tandem organization of human apolipoprotein AI, CIII and AIV genes
7. Familial disorders of high-density lipoprotein metabolism
8. Milano. Detection of normal A-I in affected subjects and evidence for a cysteine for arginine substitution in the variant A-I
9. Apolipoprotein A-I Giessen (Pro143 → Arg), a mutant that is defective in activating lecithin-cholesterol acyltransferase
10. Variant apolipoprotein A-I as a major constituent of a human hereditary amyloid
11. Apolipoprotein A-I variants: Naturally occurring substitution of proline residues affect plasma concentrations of apolipoprotein A-I
12. Isolation and characterization of human apolipoprotein A-I Fukuoka (110 Glu → Lys): A novel apolipoprotein variant
13. Characterization of a new human apolipoprotein A-I Yame by direct sequencing of polymerase chain reaction-amplified DNA
14. A mutation in the human apolipoprotein A-I gene. Dominant effect on the level and characteristics of plasma high-density lipoproteins
15. A nonsense mutation in the apolipoprotein A-I gene is associated with high-density lipoprotein deficiency and periorbital xanthelasmas
16. Apolipoprotein A-I Q(-2)X causing isolated apolipoprotein A-I deficiency in a family with analphalipoproteinemia
17. Characterization of two new human apolipoprotein A-I variants: Apolipoprotein A-I Tsushima (Trp-108 → Arg) and A-I Hita (Ala-95 → Asp)
18. A new case of apo A-I deficiency showing codon eight nonsense mutation of the apo A-I gene without evidence of coronary heart disease
19. Zavalla(Leu159 → Pro), HDL cholesterol deficiency in a kindred associated with premature coronary artery disease
20. Apo A-I Helsinki(Lys107 → 0) associated with reduced HDL cholesterol and LpA-I:A-II deficiency
21. A cysteine-containing truncated apo A-I variation associated with low HDL deficiency
22. Compound heterozygosity for a structural apolipoprotein A-I variant, apo A-I (L141R) Pisa, and an apolipoprotein null allele in patients with absence of HDL cholesterol, corneal opacifications, and coronary heart disease
23. Hereditary hepatic and systemic amyloidosis caused by a new deletion/insertion mutation in the apolipoprotein A-I gene
24. Fin, dominantly inherited hypoalphalipoproteinemia due to a single base substitution in the apolipoprotein A-I gene
25. Heterozygosity for apolipoprotein A-I (R160L) Oslo is associated with low levels of high density lipoprotein cholesterol and HDL-subclass LpA-I/A-II but normal levels of HDL subclass LpA-I
26. The replacement of arginine by cysteine at residue 151 in apolipoprotein A-I produces a phenotype similar to that of apolipoprotein A-I Milano
27. Hereditary nephropathic systemic amyloidosis caused by a novel variant apolipoprotein A-I
28. A novel homozygous missense mutation in the apo A-I gene with apo A-I deficiency
29. Zaragoza(L144R): A novel mutation in the apolipoprotein A-I gene associated with familial hypoalphalipoproteinemia
30. Human HDL cholesterol levels are determined by apo A-I fractional catabolic rate, which correlated inversely with estimates of HDL particle size
31. Automated enzymatic standardized lipid analysis for plasma and lipoprotein fractions
32. 2+ precipitation procedure for quantification of high-density-lipoprotein cholesterol
33. Metabolism of apolipoproteins A-I, A-II, and A-IV
34. Reference intervals for plasma apolipoprotein A-I determined with a standardized commercial immunoturbidimetric assay: Results from the Framingham Offspring Study
35. Differential electroimmunoassay of human LpA-I lipoprotein particles on ready-to-use plates
36. Cholesterol esterifying enzymes lecithin:cholesterol acyltransferase (LCAT) and acylcoenzyme A: Cholesterol acyltransferase (ACAT)
37. 3]leucine
38. Distribution and chemical composition of ultracentrifugally separated lipoprotein in human sera
39. Plasma apolipoprotein changes in the triglyceride-rich lipoprotein fraction of human subjects fed a fat-rich meal
40. Tracer-to-tracee ratio for analysis of stable isotope tracer data: Link with radioactive kinetic formalism
41. Evaluation of apoA-I kinetics in humans using simultaneous stable isotope and exogenous radiotracer methods
42. Human apolipoprotein AI and AII metabolism
43. Apolipoprotein A-I domains involved in lecithin-cholesterol acyltranferase activation
44. Site-directed mutagenesis and structure-function analysis of the apolipoprotein A-I relation between lecithin-cholesterol acyltransferase activation and lipid binding
45. The hydrophobic face orientation of apolipoprotein A-I amphipatic helix domain 143-164 regulates lecithin-cholesterol acyltransferase activation
46. Apolipoprotein A-IFin (Leu159 → Arg) mutation affects lecithin cholesterol acyltransferase activation and subclass distribution of HDL but not cholesterol efflux from fibroblasts
47. Seattle) alters lecithin:cholesterol acyltransferase activity and recruitment of cell phospholipid
48. Bimodal distribution of cholesteryl ester transfer protein activities in normotriglyceridemic men with low HDL cholesterol concentrations
49. An overview of reverse cholesterol transport
50. Plasma high density lipoproteins - Metabolism and relationship to atherogenesis
51. Human HDL cholesterol levels are determined by apo A-I fractional catabolic rate, which correlates inversely with estimates of HDL particle size: Effects of gender, hepatic and lipoprotein lipases, triglyceride and insulin levels, and body fat distribution
52. Apolipoprotein A-I containing lipoproteins in coronary artery disease
53. Study of lipoprotein particles LpAI and LpAI:AII in patients before coronary bypass surgery
54. A case-control study of lipoprotein particles in two populations at contrasting risk for coronary heart disease: The ECTIM study
55. Apolipoproteins, membrane cholesterol domains, and the regulation of cholesterol efflux
56. Unique epitope of apolipoprotein A-I expressed in pre-b-1 high-density lipoprotein and its role in the catalyzed efflux of cellular cholesterol
57. Identification of a sequence of apolipoprotein A-I associated with the efflux of intracellular cholesterol to human serum and apolipoprotein A-I containing particles
58. A plasma lipoprotein containing only apolipoprotein E and with γ mobility on electrophoresis releases cholesterol from cells
59. Reverse cholesterol transport in plasma of patients with different forms of familial HDL deficiency
60. Iowa, associated with hypoalphalipoproteinemia and hereditary systemic amyloidosis
61. In vivo metabolism of a mutant form of apolipoprotein, apo A-I Milano, associated with familial hypoalphalipoproteinemia
62. 107 → 0) associated with reduced HDL cholesterol and Lp(AI w AII) deficiency
63. 107 → A) exhibit enhanced fractional catabolic rate of apo A-I in Lp(AI) and apo A-II in Lp(AI with AII)
64. Metabolism of high-density lipoprotein apolipoproteins in Tangier disease
65. Physiologic mechanisms for reduced apolipoprotein A-I concentration associated with low levels of high density lipoprotein cholesterol in patients with normal plasma lipids
66. Familial HDL deficiency due to marked hypercatabolism of normal apo A-I
67. Familial HDL deficiency characterized by hypercatabolism of mature apoA-I but not proapoA-I
68. Apolipoprotein A-I metabolism in subjects with a PstI restriction fragment polymorphism of the apo A-I gene and familial hypoalphalipoproteinemia
69. Very low high-density lipoproteins without coronary atherosclerosis
70. Factors associated with low and elevated plasma high density lipoprotein cholesterol and apolipoprotein A-I levels in the Framingham Offspring Study
71. Increased apo A-I and apo A-II fractional catabolic rate in patients with low high density lipoprotein-cholesterol levels with or without hypertriglyceridemia
72. Apolipoprotein A-II production rate is a major factor regulating the distribution of apolipoprotein A-I among HDL subclasses LpA-I and LpA-I:A-II in normolipidemic humans